| Project/Area Number |
24659409
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATO Hiroshi 東北大学, 大学院薬学研究科, 教授 (60215829)
SATO Emiko 東北大学, 大学院薬学研究科, 助教 (20466543)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 高血圧 / 蛋白尿 / 妊娠 / 流産 / 子宮内胎児発育不全 / 国際情報交換 / タンパク尿 |
|---|
| Research Abstract |
Pre-eclampsia (PE), hypertension and proteinuria developing after 20 weeks of gestation, is the cause of maternal and fetal deaths. The only definitive treatment currently available to save the mother and/or the baby is induced delivery. Anti-hypertensives acceptable for use during pregnancy help control maternal blood pressure in PE, but they do not prevent pre-term delivery nor correct the fetal growth restriction associated with PE. We have demonstrated that nicotinamide reduces the hypertension and proteinuria in mice having a pre-eclampsia-like condition, delays miscarriages and alleviates the fetal growth restriction. Nicotinamide is the first substance that benefits both mother and offspring by targeting a pathway specifically dysfunctional in PE. It merits evaluation for preventing or treating PE in humans.
|
